» Articles » PMID: 21864998

Pneumocystis Jirovecii Colonization and Infection Among Non HIV-infected Patients

Overview
Journal Med Mal Infect
Publisher Elsevier
Date 2011 Aug 26
PMID 21864998
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective And Method: The epidemiology of pneumocystosis has changed in the last decade with a decreased incidence in HIV infected patients, and the emerging concept of Pneumocystis colonization. The study objective was to describe Pneumocystis infection as well as colonization among non-HIV infected patients in the Rouen teaching hospital and cancer institute. A retrospective study was made of all patients with a positive respiratory sample for Pneumocystis jirovecii between January 1, 2000 and June 6, 2007.

Results: Fifty-four cases were reported (46 cases of pneumocystosis and eight of asymptomatic carriage) and an increasing yearly incidence over the study period was observed. Underlying diseases for pneumocystosis were haematological malignancies (n=25; 54%), organ transplantation (n=8; 17.4%), inflammatory disorders (n=6; 13%), and solid cancer (n=5; 10.8%). Sixty-five per cent of patients were under long-term steroid therapy. The overall mortality rate was 21.4%. The CD4 count for 26 patients, ranged from 18 to 1449/mm(3) (median: 107). Eight cases of asymptomatic carriage were reported with an underlying immunodepression (n=6) and pulmonary disease (n=2).

Discussion: The increasing incidence of pneumocystosis in immunosuppressed patients without AIDS is due to more frequent favorable conditions and progress of diagnostic tools. The clinical presentations are severe. Prophylaxis is badly codified because there is no threshold value for CD4 count. Colonization could present a warning value.

Citing Articles

Molecular and microscopy detection of in hospitalized patients during the COVID-19 pandemic.

Matouri R, Aboutalebian S, Nasri E, Sadeghi S, Rostami S, Fakhim H Front Med (Lausanne). 2023; 10:1148320.

PMID: 37089605 PMC: 10117983. DOI: 10.3389/fmed.2023.1148320.


Epidemiological and clinical characteristics of immunocompromised patients infected with Pneumocystis jirovecii in a twelve-year retrospective study from Norway.

Gronseth S, Rogne T, Hannula R, Asvold B, Afset J, Damas J BMC Infect Dis. 2021; 21(1):659.

PMID: 34233631 PMC: 8262122. DOI: 10.1186/s12879-021-06144-1.


Pneumocystis jirovecii Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus.

Lagrou K, Chen S, Masur H, Viscoli C, Decker C, Pagano L Clin Infect Dis. 2021; 72(Suppl 2):S114-S120.

PMID: 33709126 PMC: 8243279. DOI: 10.1093/cid/ciaa1805.


Molecular Diagnosis of Pneumonia by Use of Oral Wash Samples in Immunocompromised Patients: Usefulness and Importance of the DNA Target.

Goterris L, Mancebo Fernandez M, Aguilar-Company J, Falco V, Ruiz-Camps I, Martin-Gomez M J Clin Microbiol. 2019; 57(12).

PMID: 31578265 PMC: 6879283. DOI: 10.1128/JCM.01287-19.


Detection of Pneumocystis jirovecii by Quantitative PCR To Differentiate Colonization and Pneumonia in Immunocompromised HIV-Positive and HIV-Negative Patients.

Fauchier T, Hasseine L, Gari-Toussaint M, Casanova V, Marty P, Pomares C J Clin Microbiol. 2016; 54(6):1487-1495.

PMID: 27008872 PMC: 4879311. DOI: 10.1128/JCM.03174-15.